JAMA writers call for medical groups to sever financial ties to industry

A group of distinguished medical leaders have called on professional medical associations (PMAs) to radically alter their relationship with industry. The Special Communication appeared in JAMA and was co-authored by a diverse group of writers, including first author David Rothman, of the Institute on Medicine as a Profession at Columbia University, JAMA editor Catherine DeAngelis,…

Click here to continue reading…

ACTIVE A: clopidogrel + aspirin better than aspirin alone in AF

For AF patients who can’t take warfarin, the combination of clopidogrel and aspirin is better than aspirin alone, according to results of the ACTIVE A trial, which was presented in Orlando at the ACC this morning. Stroke was reduced by 28% and MI by 23% in the 7,554 patients who were randomized in the trial….

Click here to continue reading…

AURORA: no new dawn for hemodialysis patients taking rosuvastatin

Rosuvastatin had no beneficial effect on cardiovascular events in 2,776 hemodialysis patients, according to the results of the AURORA trial, presented in Orlando at the ACC and published simultaneously in the New England Journal of Medicine….

Click here to continue reading…

TIPS: promising phase II trial for polypill

The polypill is back. Results of a phase II study presented at the ACC and published online in the Lancet suggest that a polypill could cut cardiovascular risk and reduce events. The polypill is a combination of three low dose antihypertensives (12.5 mg HCTZ, 50 mg atenolol, and 5 mg ramipril), a statin (20 mg…

Click here to continue reading…

Arena reports postive phase 3 results for locaserin

This morning Arena Pharmaceuticals announced positive results from the first of its two pivotal trials of locaserin, its anti-obesity drug that has been the subject of intense speculation. We’re too busy covering all the cardiology news at the ACC in Orlando to look at this closely right now, but you can read the press release…

Click here to continue reading…

Study shows proof of concept of renal denervation for resistant hypertension

Catheter-based renal denervation to treat resistant hypertension is feasible and safe, according to a study presented at the ACC and published online in the Lancet. The authors conclude:…

Click here to continue reading…

EARLY ACS: no benefit and increased bleeding with early eptifibatide

Early adminstration of eptifibatide is no better than delayed, provisional administration in patients with ACS without ST-segment elevation assigned to an invasive strategy.  There were more bleeding events and transfusions in the early eptifibatide group….

Click here to continue reading…

Even more JUPITER: CRP and LDL equally influence outcome

Reductions in CRP and LDL are equally effective in predicting the efficacy of rosuvastatin, according to an analysis of the JUPITER study presented at the ACC and published online in the Lancet. The best results were observed in subjects who had large reductions in both LDL and CRP. In their conclusion, the authors note that…

Click here to continue reading…

More JUPITER: rosuvastatin also prevents VTE

Rosuvastatin lowers the rate of symptomatic venous thromboembolism (VTE) in healthy people with low LDL cholesterol and high CRP levels, according to the latest results of the JUPITER study, presented in Orlando at the ACC and published simultaneously in the New England Journal of Medicine. Among 17,802 people, VTE occurred in 60 patients treated with…

Click here to continue reading…

PRE-RELAX-AHF: promising phase II results for relaxin in HF

Relaxin, a hormone that helps regulate the cardiovascular system during pregnancy, may be beneficial in acute heart failure patients with normal or elevated blood pressure, according to a phase II study published online in the Lancet. In an accompanying editorial, Chris Granger and Adrian Hernandez say that relaxin deserves further investigation, but warn that the…

Click here to continue reading…

FIX-HF-5: trial misses endpoint, but hope remains for cardiac contractility modulation in HF

FIX-HF-5, a study of cardiac contractility modulation (CCM) using a new implantable device that delivers electrical impulses to class 3 and 4 heart failure patients, missed its primary endpoint, but William Abraham, the primary investigator, told an ACC news conference that the device showed enough promise that it should continue to be developed. Results were…

Click here to continue reading…

STICH: SVR provides no added benefit to CABG

Surgical ventricular reconstruction (SVR) produces no further benefit when added to CABG in patients with ischemic heart failure, according to results from the STICH (Surgical Treatment for Ischemic Heart Failure) Hypothesis 2 trial. The results were presented at the ACC and published online in the New England Journal of Medicine. SVR succeeded in reducing LV…

Click here to continue reading…

JAMA editors now subject of AMA investigation

In response to growing concerns that JAMA editors Catherine DeAngelis and Phil Fontanarosa may have responded inappropriately to a researcher who publicly pointed out an undisclosed conflict of interest of a JAMA author, the AMA, which owns the journal, has asked an oversight committee to investigate the affair. This latest episode in the ongoing saga…

Click here to continue reading…

SYNTAX: PCI begins to gain over CABG in new analysis

Although CABG beat PCI on points in the first round of the SYNTAX matchup (the one year clinical results were previously published in the New England Journal of Medicine), the judges have now awarded the second round  to PCI. Results of the SYNTAX one year quality of life and economic analyses were presented in Orlando…

Click here to continue reading…

PROTECT AF: new device may offer alternative to warfarin for AF patients

A new implantable device may help patients with nonvalvular AF avoid warfarin therapy, according to results of the Embolic Protection in Patients with Atrial Fibrillation (PROTECT AF) trial. The trial was presented today in Orlando at the ACC Scientific Sessions. The new device, called the Watchman, blocks the left atrial appendage with a fabric-covered expandable…

Click here to continue reading…

NCDR registry supports DES over BMS in elderly patients

Patients who received drug-eluting stents had significantly better outcomes than patients who received bare metal stents, according to results from the National Cardiovascular Data Registry. The data, taken from Medicare claims, is being presented at a late-breaking clinical trial session in Orlando and has been published online in JACC….

Click here to continue reading…

ACC in Orlando: March Madness starts Saturday

CardioBrief will be blogging from Orlando starting Saturday. If you want to know what to expect you can take a look at: A Wall Street Journal preview by Ron Winslow A preview article by Peter Loftus and Jon Kamp on Dow Jones Newswires, A preview article from Heartwire by Shelley Wood Heartwire has also published…

Click here to continue reading…

Boston Scientific issues product advisories on new ICDs

Boston Scientific has issued a product advisory alert on certain models of its TELIGEN ICDs and COGNIS CRT-Ds. Here is the alert posted on the Heart Rhythm Society website: Boston Scientific Advisory & Recommendations Boston Scientific has issued a Product Advisory March 23, 2009 reporting that if the respiratory sensor of particular model numbers of…

Click here to continue reading…

Remembering Philip Poole-Wilson

Following the death earlier this month of Philip Poole-Wilson (as previously reported by CardioBrief), a number of tributes to the leading cardiologist have appeared that will be of interest to CardioBrief readers ….

Click here to continue reading…

Mehmet Oz wants to tell you your real age

A website that is popular largely due to its connection with Mehmet Oz, the Columbia University cardiac surgeon who has been dubbed “America’s Doctor” by Oprah Winfrey, is used by pharmaceutical companies and other healthcare companies to market products based on personal health data of users gathered by the site, according to a front page…

Click here to continue reading…

ACC and AHA release updated heart failure guidelines

The AHA and ACC today released a focused update of their heart failure guidelines, published online in the Journal of the American College of Cardiology and in Circulation. Key points of the updates, according to a press release from the two organizations, include:…

Click here to continue reading…

NEJM letter warns about ICD shocks caused by current leaks

In a letter in the New England Journal of Medicine, two Danish physicians write about an ICD patient who experienced an inappropriate shock in the shower due to a current leak. They warn that “inappropriate ICD shocks due to a current leak are not common, but we suspect that they may be underdiagnosed. Shocks due…

Click here to continue reading…

Case reports link stress cardiomyopathy to catecholamines and beta agonists

Stress cardiomyopathy (SCM) may be provoked by intravenous administration of catecholamines and beta-receptor agonists, according to a new study published online in the Journal of the American College of Cardiology. The findings of the observational series of 9 patients “provides compelling evidence that exaggerated sympathetic stimulation is sufficient to precipitate the syndrome of SCM in…

Click here to continue reading…

LAMP2 mutation causes severe cardiomyopathy in young patients

Young patients with Danon disease, a cardiomyopathy associated with a mutation in the LAMP2 gene, have a rapid and often fatal progression of disease, according to a new study from Barry Maron and colleagues in JAMA. In a press release, Maron called this “one of the most lethal cardiomyopathies in young and usually male patients”…

Click here to continue reading…

NICE-SUGAR: Intensive glucose control in ICU found harmful

NICE-SUGAR, published online first in the New England Journal of Medicine, randomized 6,000+ ICU patients to intensive or conventional glucose control. Mortality was 27.5% in the intensive-control group verus 24.9% in the conventional-control group, a difference that achieved statistical significance. An accompanying editorial, by Silvio Inzucchi and Mark Siegel, notes that physicians “are now left…

Click here to continue reading…